06922 康灃生物－Ｂ
按盘价 
5.660 +0.010 (+0.177%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -26.626% | -57.649% | -37.019% | -41.140% | -66.573% |
| 股东资金回报率 (%) | -61.770% | -88.703% | -48.670% | -54.771% | -92.222% |
| 资本运用回报率 (%) | -49.431% | -116.698% | -53.552% | -41.854% | -50.084% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 67.162% | 71.753% | 75.829% | 71.318% | 69.317% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -44.704% | -183.865% | -236.606% | -408.188% | -543.708% |
| 税前边际利润率 (%) | -46.664% | -207.624% | -258.232% | -435.802% | -564.064% |
| 纯利率 (%) | -40.065% | -194.962% | -238.061% | -413.356% | -454.263% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 1.514 X | 1.641 X | 4.870 X | 5.777 X | 6.695 X |
| 速动比率 (X) | 0.969 X | 1.142 X | 4.079 X | 5.341 X | 6.281 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 64.692% | 47.114% | 18.495% | 17.356% | 14.975% |
| 总债项 / 总资产比率 (%) | 19.061% | 29.028% | 5.174% | 3.623% | 3.885% |
| 净债项 / 总资产比率 (%) | -6.426% | -1.430% | -43.413% | -68.517% | -64.251% |
| 总债项 / 股东资金比率 (%) | 52.677% | 58.666% | 6.819% | 4.755% | 5.275% |
| 长期债项 / 股东资金比率 (%) | 7.477% | 10.454% | 4.808% | 3.320% | 3.754% |
| 净债项 / 股东资金比率 (%) | -17.759% | -2.890% | -57.220% | -89.929% | -87.235% |
| 净现金 / (债项) ($) | 8.83百万 | 2.13百万 | 9.24千万 | 2.15亿 | 1.49亿 |
| 每股净现金 / (债项) ($) | 0.037 | 0.009 | 0.386 | 0.899 | -- |
| 总债项 / 资本运用比率 (%) | 33.930% | 48.444% | 6.049% | 4.241% | 4.425% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 366.062日 | 654.470日 | 816.475日 | 741.156日 | 525.115日 |
| 应收贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 7.080日 | 7.197日 | 11.895日 | 13.962日 | 4.061日 |
| 备注： | 实时报价更新时间为09/04/2026 16:58 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -38,169 |
| 增长率 | -63.427% |
| 每股盈利/(亏损) | RMB -0.160 |
| 每股账面资产净值 (¥) | RMB 0.208 |